Piscataway, N.J. – Camber Pharmaceuticals has announced the addition of roflumilast tablets to its current portfolio.

Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis.

Roflumilast tablets from Camber are available in 500 mcg strength in 30 and 90 count bottles.